Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451149 | 0.80 | LMNA (0.61) | LMNAHTTCARM1PRMT5WDR77 | |
| SCHEMBL5454423 | 0.80 | DRD2 (0.50) | DRD2DRD1DRD5DRD3CARM1 | |
| SCHEMBL5456128 | 0.78 | ALDH1A1 (0.59) | — | |
| SCHEMBL5453481 | 0.77 | GGT1 (0.49) | CARM1PRMT5WDR77 | |
| SCHEMBL5456100 | 0.77 | MEN1 (0.46) | DRD2 | |
| SCHEMBL8506825 | 0.77 | SIGMAR1 (0.50) | DRD2DRD1DRD5DRD3 | |
| SCHEMBL5750755 | 0.77 | DRD1 (0.44) | DRD2DRD1DRD5DRD3 | |
| SCHEMBL5456384 | 0.75 | CACNA1B (0.55) | LMNADRD2DRD1DRD5DRD3 | |
| SCHEMBL5451934 | 0.75 | PNMT (0.56) | DRD2DRD1DRD5DRD3 | |
| SCHEMBL7318999 | 0.73 | CACNA1B (0.62) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | LMNA 1282/4885HTT 1961/4885DRD2 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.